Ironwood Pharmaceuticals, Inc. $IRWD Shares Purchased by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC increased its holdings in shares of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 454.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 79,512 shares of the biotechnology company’s stock after acquiring an additional 65,172 shares during the quarter. Pallas Capital Advisors LLC’s holdings in Ironwood Pharmaceuticals were worth $57,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Armistice Capital LLC raised its stake in Ironwood Pharmaceuticals by 44.7% during the first quarter. Armistice Capital LLC now owns 13,700,000 shares of the biotechnology company’s stock worth $20,139,000 after purchasing an additional 4,232,000 shares during the period. Millennium Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 186.6% in the 1st quarter. Millennium Management LLC now owns 6,359,682 shares of the biotechnology company’s stock valued at $9,349,000 after acquiring an additional 4,140,439 shares during the period. Jane Street Group LLC raised its stake in shares of Ironwood Pharmaceuticals by 740.5% in the 1st quarter. Jane Street Group LLC now owns 3,510,117 shares of the biotechnology company’s stock valued at $5,160,000 after acquiring an additional 3,092,475 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Ironwood Pharmaceuticals by 33.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,647,015 shares of the biotechnology company’s stock valued at $3,891,000 after acquiring an additional 663,775 shares during the period. Finally, Acadian Asset Management LLC raised its stake in shares of Ironwood Pharmaceuticals by 160.7% in the 1st quarter. Acadian Asset Management LLC now owns 2,645,189 shares of the biotechnology company’s stock valued at $3,878,000 after acquiring an additional 1,630,726 shares during the period.

Wall Street Analysts Forecast Growth

IRWD has been the topic of several recent research reports. Wall Street Zen raised shares of Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 9th. Zacks Research downgraded shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 5th. One equities research analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $4.94.

Ironwood Pharmaceuticals Stock Performance

IRWD stock opened at $1.39 on Wednesday. Ironwood Pharmaceuticals, Inc. has a one year low of $0.53 and a one year high of $5.13. The stock has a market capitalization of $225.78 million, a PE ratio of -27.79 and a beta of 0.33. The company has a fifty day moving average of $1.07 and a 200-day moving average of $0.96.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Thursday, August 7th. The biotechnology company reported $0.14 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.16. Ironwood Pharmaceuticals had a negative net margin of 2.25% and a negative return on equity of 2.46%. The company had revenue of $85.24 million during the quarter, compared to analysts’ expectations of $62.02 million. Ironwood Pharmaceuticals has set its FY 2025 guidance at EPS. Equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.1 earnings per share for the current fiscal year.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.